<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2155">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844855</url>
  </required_header>
  <id_info>
    <org_study_id>1608068</org_study_id>
    <secondary_id>2016-A00891-50</secondary_id>
    <nct_id>NCT02844855</nct_id>
  </id_info>
  <brief_title>Memory for Action in Neurological Patients</brief_title>
  <acronym>EMBODIMENT</acronym>
  <official_title>Memory for Action in Neurological Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Memory for action is especially important in everyday life although current literature is not&#xD;
      very abundant. The enactment effect (i.e. better memory for performed actions than for&#xD;
      verbally encoded sentences) is usually described as a robust effect in aging and can be found&#xD;
      in many diseases. Although the enactment effect has been studied for three decades, there is&#xD;
      still no consensus on how it enhances memory. Therefore, in order to gain additional insight&#xD;
      into the representational basis of the enactment effect, in the present study, the&#xD;
      investigators propose to test neurological patients. The investigators suggested that memory&#xD;
      for action should be better than memory for verbally encoded information in Alzheimer's&#xD;
      disease and Parkinson's disease.&#xD;
&#xD;
      If patients with Alzheimer's disease (AD) and Parkinson's disease (PD) have no cognitive&#xD;
      assessment during the last 6 months, then they will realize different tests: MMSE (1), HAD&#xD;
      (2), a cognitive assessment (3); (4); BREF (5); Assessment of apraxia, (6). Controls will&#xD;
      perform the same tests to verify that they have no cognitive impairment. Then, two&#xD;
      experimental conditions will be presented in all patients and controls: a first in which&#xD;
      participants will have to name drawings (verbal learning) and a second in which they will&#xD;
      have to reproduce an action associated with drawings (action learning). Immediately after&#xD;
      this learning phase, a recognition task will be available and therefore participants will&#xD;
      have to recognize drawings that had been presented previously. The main criteria used in the&#xD;
      statistical analysis will be the correct recognition score.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. = Folstein et al., 1975,&#xD;
&#xD;
        2. = Zigmond &amp; Snaith, 1983,&#xD;
&#xD;
        3. = Dubois et al., 2002;&#xD;
&#xD;
        4. = Godefroy et al., 2008;&#xD;
&#xD;
        5. = Dubois et Pillon, 2000;&#xD;
&#xD;
        6. = Mahieux-Laurent, 2009.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    failure to recruit 83/99&#xD;
  </why_stopped>
  <start_date type="Actual">December 26, 2016</start_date>
  <completion_date type="Actual">February 21, 2020</completion_date>
  <primary_completion_date type="Actual">February 21, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of correct answers</measure>
    <time_frame>Day 1</time_frame>
    <description>The gain provided by the verbal learning vs action learning (number of correct answers).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>patients with Alzheimer disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Behavioral: Cognitive tests Only patients with Alzheimer disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond &amp; Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with Parkinson disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Behavioral: Cognitive tests Only patients with Parkinson disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond &amp; Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Behavioral: Cognitive tests Only patients with healthy controls will be included in this arm. Controls will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond &amp; Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive tests</intervention_name>
    <description>MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond &amp; Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).</description>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>patients with Alzheimer disease</arm_group_label>
    <arm_group_label>patients with Parkinson disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for 3 arms:&#xD;
&#xD;
          -  Patient affiliated to a social security system&#xD;
&#xD;
          -  Age between 55 and 80 years&#xD;
&#xD;
          -  Normal vision and hearing or successfully corrected&#xD;
&#xD;
          -  French mother tongue&#xD;
&#xD;
          -  Signature of consent by participants&#xD;
&#xD;
        Specific criteria for inclusion of MA patients:&#xD;
&#xD;
          -  Probable AD diagnosis made by a neurologist (McKhann et al., 2011)&#xD;
&#xD;
          -  Mini-Mental State Examination (MMSE): score &gt; 22&#xD;
&#xD;
          -  Stable treatment for two months minimum.&#xD;
&#xD;
        Specific criteria for inclusion of PD patients:&#xD;
&#xD;
          -  PD diagnosed by a neurologist (Postuma et al., 2015)&#xD;
&#xD;
          -  Stable treatment for two months minimum.&#xD;
&#xD;
          -  Mini-Mental State Examination (MMSE): score &gt; 27&#xD;
&#xD;
          -  Under dopaminergic treatment&#xD;
&#xD;
        Exclusion Criteria for 3 arms:&#xD;
&#xD;
          -  Other neurological or psychiatric history&#xD;
&#xD;
          -  Anxiety and depressive symptoms (assessed by the scale of depression-anxiety HAD;&#xD;
             Zigmond &amp; Snaith, 1983)&#xD;
&#xD;
          -  Inability to communicate&#xD;
&#xD;
          -  Significant impairment of judgment&#xD;
&#xD;
          -  Delusional or psychotic state&#xD;
&#xD;
        Criteria common for non-inclusion of AD and PD patients:&#xD;
&#xD;
          -  Other neurological or psychiatric history&#xD;
&#xD;
          -  Anxiety and depressive symptoms (assessed by the scale of depression-anxiety HAD;&#xD;
             Zigmond &amp; Snaith, 1983)&#xD;
&#xD;
          -  Inability to communicate&#xD;
&#xD;
          -  Significant impairment of judgment&#xD;
&#xD;
          -  Delusional or psychotic state&#xD;
&#xD;
        Criteria for non-inclusion of PD patients:&#xD;
&#xD;
        - Motor fluctuations&#xD;
&#xD;
        Criteria for non-inclusion of controls:&#xD;
&#xD;
          -  Psychiatric or neurological disorders&#xD;
&#xD;
          -  Anxiety and depressive symptoms (assessed by the scale of depression-anxiety HAD;&#xD;
             Zigmond &amp; Snaith, 1983)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CÃ©line BORG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>celine.borg@univ-st-etienne.fr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hcl - Cm2R</name>
      <address>
        <city>Villeurbanne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 22, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer</keyword>
  <keyword>Parkinson</keyword>
  <keyword>Action memory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

